<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01308294</url>
  </required_header>
  <id_info>
    <org_study_id>P009-2010DR1082</org_study_id>
    <nct_id>NCT01308294</nct_id>
  </id_info>
  <brief_title>Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients</brief_title>
  <acronym>LAG-3/IMP321</acronym>
  <official_title>Vaccination of Melanoma Patients (Stage II-IV) With ImmuFact IMP321, Tumor Antigenic Peptides and Montanide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immutep S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether vaccination with tumor antigenic peptides
      and both IMP321/LAG-3 and Montanide adjuvants can induce an immune response in melanoma
      patients and to assess the safety and tolerability of this vaccination. Tumor responses
      following this vaccination will also be documented.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enrollment rate
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of vaccination will be assessed according to NCI CTC scale</measure>
    <time_frame>Change from baseline at week 31</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunological response (tumor antigen specific CD4 and CD8 T cell reactivity) will be measured by Tetramer analysis and ELISpot assays</measure>
    <time_frame>Change from baseline in CD8 T cells reactivity at week 31</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response will be assessed by radiology in patients with measurable disease</measure>
    <time_frame>Change from baseline in tumor response at week 31</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 vaccine injections in same limb (vaccine 1 : NY-ESO-1, MAGE-3.A2, NA-17 peptides + IMP321 + Montanide) (vaccine 2 : Melan-A, MAGE-A3-DP4 peptides + IMP321 + Montanide)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 vaccine injections in different limbs (vaccine 1: NY-ESO-1, MAGE-3.A2, NA-17 peptides + IMP321 + Montanide) (vaccine 2: Melan-A, MAGE-A3-DP4 peptides + IMP321 + Montanide)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 vaccine injections in different limbs (vaccine 1: NY-ESO-1, MAGE-3.A2, NA-17 peptides + IMP321 + Montanide) (vaccine 2: Melan-A peptide + IMP321 + Montanide)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2 vaccine injections in 1 limb</intervention_name>
    <description>All participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide. The content of each syringe is injected s.c. in the same limb at about 5 cm distance from each other.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2 vaccine injections in different limbs</intervention_name>
    <description>All participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide.The content of each syringe is injected s.c. in different limbs.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2 vaccine injections in different limbs, the vaccine does not contain the MHC class II peptide MAGE-A3-DP4</intervention_name>
    <description>All participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A peptide with IMP321/LAG-3 ± Montanide. The content of each syringe is injected s.c. in different limbs.</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed stage II, III or IV melanoma patients.

          -  Tumor expression of Melan-A.

          -  Human leukocyte antigen-A2 (HLA-A2) positive.

          -  Expected survival of at list 3 months.

          -  Karnofsky scale performance status of 70 % or more.

          -  Age ≥ 18 years.

          -  Able to give a written informed consent.

          -  The following laboratory results:

        Hemoglobin ≥ 100g/L Neutrophil count ≥ 1.5 x 109/L Lymphocyte count ≥ 0.5 x 109/L Platelet
        count ≥ 100 x 109/L Serum creatinine ≤ 2 mg/dL (0.18mmol/L) Serum bilirubin ≤ 2mg/dL
        (0.034mmol/L) Granulocyte count &gt; 2.5x109/L ASAT, ALAT &lt; 2.5 x upper limit of normal aPTT
        within the normal ranges ±25% TP ≥ 80%

        Exclusion Criteria:

          -  Clinically significant heart disease.

          -  Serious illness, eg. serious infections requiring antibiotics, uncontrolled peptic
             ulcer, or central nervous system disorders.

          -  History of immunodeficiency disease or autoimmune disease.

          -  Metastatic disease to the central nervous system, unless treated and stable.

          -  Known HIV positivity.

          -  Known seropositivity for hepatitis B surface antigen.

          -  Concomitant treatment with steroids, antihistamine drugs. Topical or inhalation
             steroids are permitted.

          -  Participation in any other clinical trial involving another investigational agent
             within 4 weeks prior to enrollment.

          -  Pregnancy or lactation.

          -  Women of childbearing potential not using a medically acceptable means of
             contraception.

          -  Psychiatric or addictive disorders that may compromise the ability to give informed
             consent.

          -  Lack of availability of the patient for immunological and clinical follow-up
             assessment.

          -  Coagulation or bleeding disorders.

          -  Kidney dysfunction with creatinine &gt; 2 X the upper limit of the normal value.

          -  Reported strong (allergic) reactions to previous vaccination.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Michielin, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oncology Department, CHUV</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.cancer-chuv.ch/ccl_home.htm</url>
    <description>Multidisciplinary Oncology Center, CHUV, Lausanne</description>
  </link>
  <reference>
    <citation>Sierro S, Romero P, Speiser DE. The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets. 2011 Jan;15(1):91-101. doi: 10.1517/14712598.2011.540563. Review.</citation>
    <PMID>21142803</PMID>
  </reference>
  <reference>
    <citation>Brignone C, Escudier B, Grygar C, Marcu M, Triebel F. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res. 2009 Oct 1;15(19):6225-31. doi: 10.1158/1078-0432.CCR-09-0068. Epub 2009 Sep 15.</citation>
    <PMID>19755389</PMID>
  </reference>
  <reference>
    <citation>Speiser DE, Romero P. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Semin Immunol. 2010 Jun;22(3):144-54. doi: 10.1016/j.smim.2010.03.004. Epub 2010 Apr 21. Review.</citation>
    <PMID>20413326</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2011</study_first_submitted>
  <study_first_submitted_qc>March 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2011</study_first_posted>
  <last_update_submitted>October 14, 2014</last_update_submitted>
  <last_update_submitted_qc>October 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Prof Olivier Michielin, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>Stage II-IV</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Vaccination</keyword>
  <keyword>HLA class I and II tumor-specific peptides</keyword>
  <keyword>IMP321</keyword>
  <keyword>Montanide ISA-51 VG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 12, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

